NEW YORK, August 29, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
--
Celgene Corporation Research Reports
On August 21, 2014, Celgene Corporation (Celgene) announced that its management will provide an overview of the Company at the two upcoming investor conferences - 9th Annual Citi Biotech Conference scheduled on September 4, 2014 at 10:00 a.m. ET in Boston; and Morgan Stanley Global Healthcare Conference on September 9, 2014 at 12:55 p.m. ET in New York. Celgene informed that the live webcasts of both the conferences will be available on the Company's official website under Investor Relations section. The full research reports on Celgene are available to download free of charge at:
http://www.analystsreview.com/Aug-29-2014/CELG/report.pdf
--
Actavis plc Research Reports
On August 26, 2014, Actavis plc (Actavis) reported that its President and CEO, Brenton Saunders will provide an update and overview of the Company's business during a presentation at the forthcoming Morgan Stanley Global Healthcare Conference 2014 on September 9, 2014 at 11:10 a.m. ET at the Grand Hyatt New York, 109 East 42nd Street, New York, NY 10017. The Company informed that the live webcast the presentation will be available through the Investor Relations section of Actavis' official website. The full research reports on Actavis are available to download free of charge at:
http://www.analystsreview.com/Aug-29-2014/ACT/report.pdf
--
Regeneron Pharmaceuticals Inc. Research Reports
On August 25, 2014, Regeneron Pharmaceuticals Inc. (Regeneron) and Sanofi jointly announced that the details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, on August 31, 2014. In addition, the Company will also highlight the data in the official ESC press conference on August 31, 2014 at 03:00 ET (09:00 CET). The Company stated that Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). In addition, both Regeneron and Sanofi will host an IR Thematic Conference Call for the financial community focusing on alirocumab on September 2, 2014 at 8:30 ET through 9:30 ET (14:30 CET through 15:30 CET). The full research reports on Regeneron are available to download free of charge at:
http://www.analystsreview.com/Aug-29-2014/REGN/report.pdf
--
ISIS Pharmaceuticals, Inc. Research Reports
On August 15, 2014, ISIS Pharmaceuticals, Inc. (ISIS) announced that it has received $2 million as milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA). The Company stated that the open-label extension study of ISIS-SMNRx is offered to those children with SMA who have completed dosing in Isis' previous studies. In this study, children with SMA are receiving a 12 mg dose of ISIS-SMNRx every six months for the duration of the study. The full research reports on ISIS are available to download free of charge at:
http://www.analystsreview.com/Aug-29-2014/ISIS/report.pdf
--
UnitedHealth Group Inc. Research Reports
On August 21, 2014, UnitedHealth Group Inc. (UnitedHealth) reported the expansion of its partnership with New York State 4-H Youth Development named Eat4-Health that helps in tackling obesity by promoting healthy eating and active lifestyles among youth and families. Further, the Company is granting $40,000 to Cornell University Cooperative Extension, which administers 4-H programs, to support youth healthy-living programs. The Company informed that a part of this grant will be used to support healthy living programming, which includes the purchase of pedal-powered blender bikes through which young people can create their own healthy smoothies through exercise. The grant will also support community events and programs this summer through spring 2015 in which youth and families can learn about easy ways to promote healthy lifestyles. The full research reports on UnitedHealth are available to download free of charge at:
http://www.analystsreview.com/Aug-29-2014/UNH/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
